Cyclacel Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.cyclacel.com
- Introduction
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Cyclacel Completes Enrollment in Fadraciclib Trial for Tumors with CDKN2A/B Abnormalities
Cyclacel Pharmaceuticals completed enrollment in Cohort 8 of its Phase 2 trial of fadraciclib, a CDK2/9 inhibitor, focusing on patients with advanced solid tumors and lymphoma exhibiting CDKN2A/B abnormalities.